United States: Licensing & Syndication

Subscribe
Intellectual property law and copyright law thought leadership, articles, podcasts, videos and webinars from expert sources across the legal world. Explore insights covering topics such as licensing and syndication, patent law, trade secrets and trademark law.
Article
AI In The Art Market, Part 3: Human Creativity And Authenticity
As AI-generated art becomes increasingly sophisticated and visible in institutions like Dataland, the art world grapples with fundamental questions about distinguishing human creativity from machine output. This analysis explores the legal, commercial, and reputational implications for copyright protection, market positioning, disclosure obligations, and the evolving regulatory landscape surrounding AI use in creative industries.
United States IP
HK
Holland & Knight
Article
Intellectual Property Report
From Lululemon's strategic response to dupe culture to landmark trade dress victories and AI-powered patent analysis, this intellectual property report examines how brands are adapting their protection strategies in an era of social media influence and technological transformation. The collection explores critical developments in trademark law, patent prosecution, and the evolving intersection of artificial intelligence with IP due diligence.
United States IP
BB
Baker Botts LLP
Article
Patents And University Spin-outs: Protecting Academic Innovation
Universities drive innovation across medicine, AI, materials, and clean tech, but academic researchers face a critical challenge: the need to publish conflicts with patent protection requirements for confidentiality. Understanding how to navigate publication deadlines, filing strategies, and IP development can determine whether groundbreaking research becomes a valuable commercial asset or loses protection entirely.
United States IP
JA
J A Kemp LLP
Article
Understanding IP – Some Common Misconceptions
Many businesses hold misconceptions about their intellectual property portfolios that can lead to costly mistakes. From misunderstanding what patent rights actually provide to believing computer programs cannot be patented, these myths can prevent companies from maximizing the value of their IP assets. Understanding the true nature of patent protection and the importance of strategic IP management is essential for businesses seeking to leverage their innovations effectively.
United States IP
JA
J A Kemp LLP
Article
VDPP v. Volkswagen: The Patent Marking Mistake That Erased Millions In Damages
When you settle a patent dispute or license your technology, you may unknowingly trigger patent marking obligations that can eliminate your ability to recover pre-suit damages. A recent Federal Circuit decision demonstrates how settlement agreements transform patent owners into licensors with active compliance duties, and why failing to monitor licensee marking practices can result in case dismissal and substantial attorney fee awards.
United States IP
NP
NovoTech Patent Firm
Article
Court Upholds MillerKnoll Ownership Of Iconic Bubble Lamp Design
The Sixth Circuit's decision in Nelson v. MillerKnoll examines whether a furniture company's ownership claims to the iconic Bubble Lamp design were authorized under a 2006 royalty agreement, and whether the designer's heirs ratified that arrangement by continuing to accept payments. The case hinges on interpreting contract language distinguishing between licensing rights and outright ownership of intellectual property.
United States IP
FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Article
How Intellectual Property Valuation Will Impact Business Transactions
Intellectual property valuation determines the monetary worth of intangible business assets like patents, trademarks, copyrights, and trade secrets. Understanding IP value is critical for licensing deals, mergers and acquisitions, financing arrangements, infringement disputes, and ownership conflicts. The three primary valuation methods—income, market, and cost—each serve different asset types and business scenarios.
United States IP
SH
Scarinci Hollenbeck LLC
Article
European Patent Office Updates Its Guidelines For Examination
The European Patent Office has released its April 2026 Guidelines for Examination, introducing significant changes to procedural and substantive patent law. Key updates include modifications to the PACE acceleration program, new claim interpretation standards following the G1/24 decision, relaxed novelty requirements for products placed on the market under G1/23, and refined guidance on further medical use claims under Article 54(5) EPC.
Global IP
OM
Oblon, McClelland, Maier & Neustadt, L.L.P
Article
USPTO Reinstates Double Patenting Rejections In Ex Parte Baurin: What Life Sciences Innovators Need To Know
The USPTO Appeals Review Panel's August 2026 decision in Ex parte Baurin reinstated nonstatutory double patenting rejections against Sanofi's antibody-like binding protein application, even though the application would expire before the reference patent. This precedential ruling raises critical questions about whether the risk of harassment by multiple patent owners alone justifies double patenting rejections, particularly when no extension of patent term exists.
United States IP
FH
Foley Hoag LLP
Article
What’s In A Name? The Zaha Hadid Rebrand And The Legal Architecture Of Legacy
When Zaha Hadid Architects rebranded as ZHA following a protracted legal battle with the Zaha Hadid Foundation over trademark licensing fees, it raised fundamental questions about founder succession planning in professional services firms. This article examines whether the choice between perpetual royalties and complete separation was truly the only path, proposing an innovative Equity-for-Legacy Model that could have preserved both commercial sustainability and cultural legacy through aligned ownership rat
United States IP
SM
Sheppard, Mullin, Richter & Hampton LLP
Article
Teva And Polpharma Biologics Announce Global Licensing Agreement For Ocrelizumab Biosimilar For Multiple Sclerosis
Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement for the commercialization of a biosimilar candidate to Genentech's OCREVUS (ocrelizumab), a treatment for multiple sclerosis. The agreement combines Polpharma Biologics' development expertise with Teva's commercial capabilities across major markets including the United States, Europe, and several other territories. Under the terms, Polpharma Biologics will handle development and manufacturing while Teva manages regul
United States Healthcare
GP
Goodwin Procter LLP
Article
Non-U.S. Trademark Registrants Beware!
When a non-U.S. company obtains a U.S. trademark registration based on a foreign registration without U.S. use, failing to file the required Declaration of Use within six years can result in cancellation with serious consequences. A recent TTAB decision demonstrates how a lapsed registration loses all protective value, even against later-filed confusingly similar marks that were registered while the original registration was still active.
United States IP
CL
Cowan Liebowitz & Latman PC
Article
A New Framework For AI Permissions In Entertainment: RSL Media’s Human Consent Standard
RSL Media has introduced the Human Consent Standard, a machine-readable protocol allowing individuals to declare whether AI systems may use their creative works, identity, likeness, voice, characters, or marks. While endorsed by major entertainment industry figures and organizations, the voluntary standard's effectiveness depends on pending federal legislation like the NO FAKES Act, voluntary adoption by AI developers, and its ability to withstand contractual pressures that could undermine its protective fu
United States IP
GA
Global Advertising Lawyers Alliance (GALA)
See more

Latest Videos

See more